Pasithea Therapeutics Corp (KTTA) Stock Price, Quote & News

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, includ...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 977 3380

Website: www.pasithea.com

Address:

1111 Lincoln Road, Suite 500, Miami Beach, United States

UtahSUV Jun. 15 at 2:58 PM

$KTTA the most depressing investment

0 · Reply

DARKP00L Jun. 15 at 11:34 AM

$KTTA 07:16 on Jun. 15 2026 Pasithea Therapeutics Announced It Will Participate As An Exhibitor In The Upcoming Children's Tumor Foundation 2026 Nf Conference, Held June 26-30, 2026, In Denver, Colorado #tradeideas

0 · Reply

focafoca99 Jun. 15 at 11:17 AM

$KTTA is exhibiting at the Children’s Tumor Foundation 2026 NF Conference in Denver.

0 · Reply

aletz Jun. 11 at 6:42 PM

$KTTA https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #6 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.

0 · Reply

SuperGreenToday Jun. 10 at 5:28 PM

$KTTA

0 · Reply

aletz Jun. 5 at 8:02 AM

$KTTA https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk2/ Picked in my AI Catalyst advance for the first time. Interesting set up, I'll do my own DD to learn more. Visit the link to read more and learn more about other ideas. All free.

0 · Reply

MrTicker Jun. 2 at 3:54 PM

$KTTA solid PR, low volume manipulation. could see a reversal this afternoon or after hours. keep this on watch

0 · Reply

DARKP00L Jun. 2 at 11:58 AM

$KTTA 07:08 on Jun. 02 2026 Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis #tradeideas

0 · Reply

Daniel_2025 Jun. 2 at 11:05 AM

$KTTA https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-52h4ug7jm1u9.html

0 · Reply

postless Jun. 2 at 11:05 AM

$KTTA incoming

0 · Reply

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference

2026-06-02T11:30:51.000Z - 13 days ago

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

Jun 2, 2026, 7:02 AM EDT - 13 days ago

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

2026-05-29T17:55:12.000Z - 17 days ago

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

2026-05-04T11:32:53.000Z - 6 weeks ago

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

May 4, 2026, 7:01 AM EDT - 6 weeks ago

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

2026-04-20T11:26:07.000Z - 2 months ago

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

Apr 1, 2026, 7:01 AM EDT - 2 months ago

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Feb 17, 2026, 7:01 AM EST - 4 months ago

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-13T12:11:53.000Z - 5 months ago

Pasithea Therapeutics provides updated timeline on PAS-004 programs

Jan 13, 2026, 7:01 AM EST - 5 months ago

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

2025-12-08T11:15:53.000Z - 6 months ago

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-02T16:19:00.000Z - 6 months ago

3 Penny Stocks to Watch Now, 12/2/25

ADTX BEAM

Dec 2, 2025, 7:00 AM EST - 6 months ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

2025-11-28T14:25:15.000Z - 7 months ago

Pasithea Therapeutics prices 80M shares at 75c in public offering

Nov 28, 2025, 9:20 AM EST - 7 months ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

2025-11-25T12:05:49.000Z - 7 months ago

Pasithea Therapeutics announces $1M award by ALS Association

2025-11-24T12:15:27.000Z - 7 months ago

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

Nov 24, 2025, 7:00 AM EST - 7 months ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

2025-11-21T17:40:13.000Z - 7 months ago

Pasithea says tablet PK exposure increases proprtionally with dose increase

Nov 21, 2025, 12:35 PM EST - 7 months ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

2025-11-21T14:02:21.000Z - 7 months ago

Why Is Pasithea Therapeutics Stock (KTTA) Down Today?

2025-11-20T21:05:17.000Z - 7 months ago

Pasithea Therapeutics announces interim data from PAS-004 trial

Nov 20, 2025, 4:01 PM EST - 7 months ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

2025-11-04T12:50:47.000Z - 7 months ago

Pasithea announces activation of trial site at UAB for study of PAS-004

Nov 4, 2025, 7:03 AM EST - 7 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

2025-09-16T11:15:43.000Z - 9 months ago

Pasithea Therapeutics announces activation of two South Korean trial sites

Sep 16, 2025, 7:03 AM EDT - 9 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

2025-09-08T11:11:03.000Z - 10 months ago

Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004

Aug 29, 2025, 8:39 AM EDT - 10 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

2025-07-31T11:22:57.000Z - 11 months ago

Pasithea completes enrollment, initial dosing from Phase 1/1b trial of PAS-004

Jul 31, 2025, 7:01 AM EDT - 11 months ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

2025-06-11T11:20:21.000Z - 1 year ago

Pasithea Therapeutics appoints Lee to its SAB

Jun 11, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 2, 2025, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

May 20, 2025, 7:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 14, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 7, 2025, 5:00 PM EDT - 1 year ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 1 year ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 7:03 AM EDT - 1 year ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Apr 29, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 24, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 10, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Jan 14, 2025, 8:02 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

May 28, 2024, 6:59 AM EDT - 2 years ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Feb 13, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 7, 2023, 4:14 PM EDT - 3 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Aug 1, 2023, 7:59 AM EDT - 3 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Jul 20, 2023, 8:43 AM EDT - 3 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:40 AM EDT - 3 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jun 30, 2023, 9:28 AM EDT - 3 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

UtahSUV Jun. 15 at 2:58 PM

$KTTA the most depressing investment

0 · Reply

DARKP00L Jun. 15 at 11:34 AM

0 · Reply

focafoca99 Jun. 15 at 11:17 AM

$KTTA is exhibiting at the Children’s Tumor Foundation 2026 NF Conference in Denver.

0 · Reply

aletz Jun. 11 at 6:42 PM

0 · Reply

SuperGreenToday Jun. 10 at 5:28 PM

$KTTA

0 · Reply

aletz Jun. 5 at 8:02 AM

0 · Reply

MrTicker Jun. 2 at 3:54 PM

$KTTA solid PR, low volume manipulation. could see a reversal this afternoon or after hours. keep this on watch

0 · Reply

DARKP00L Jun. 2 at 11:58 AM

$KTTA 07:08 on Jun. 02 2026 Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis #tradeideas

0 · Reply

Daniel_2025 Jun. 2 at 11:05 AM

$KTTA https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-52h4ug7jm1u9.html

0 · Reply

postless Jun. 2 at 11:05 AM

$KTTA incoming

0 · Reply

Tankman22 Jun. 2 at 11:04 AM

$CTNT most likely stop losses triggers from Robinhood brokers… watching for some base here … still think we can squeeze to 4 bulls $BJDX $KTTA $VSA $ABTS

0 · Reply

crainiac Jun. 1 at 12:56 PM

$KTTA More news - KTTA gets World Patent application published for Tablet formulation to treat cancer and heart disease https://www.freepatentsonline.com/WO2026112507A1.html

0 · Reply

BOUDIN420 May. 31 at 6:20 PM

$KTTA

0 · Reply

TradeHawk May. 29 at 5:49 PM

$KTTA Pasithea Therapeutics Corp. has received FDA Orphan Drug Designation for PAS004 (Mitogen-activated Protein Kinase (mapk)/extracellular Signal-related Kinase (erk) Kinase 1/ 2 (mek1/2) Inhibitor) for treatment of amyotrophic lateral sclerosis. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326

1 · Reply

Zskylar May. 29 at 12:38 PM

$KTTA little life

0 · Reply

frontiere May. 19 at 7:31 PM

$KTTA Pasithea ref=$0.71 today — bought some Long with room to add down to $0.30s (the recent fast lows) — swing targets to recent spike highs. 👍 Eligible for PRV on approval (~ $ 200m value in recent transactions!) for PAS-004 MEK in NF1 👍 Ph1/1b (open label!) PAS-004 MEK in NF1, last updated 2025-12 https://clinicaltrials.gov/study/NCT06961565 👍 Ph1 (open label!) PAS-004 MEK in Advanced solid tumors, last updated 2025-12 https://clinicaltrials.gov/study/NCT06299839 Latest corp deck Jan 2026 https://d1io3yog0oux5.cloudfront.net/_9eb9e0c43a5e9f7336232217c4b21e0c/pasithea/db/1912/17754/pdf/Pasithea+Corporate+Deck+%28Jan+2026%29+.pdf Apr 20 PR granted RPDD and PRV eligible https://ir.pasithea.com/news-events/press-releases/detail/139/pasithea-therapeutics-announces-grant-of-rare-pediatric

0 · Reply

LewisDaKat May. 16 at 11:30 AM

$KTTA Expected earnings - Pasithea Therapeutics Corp. https://marketwirenews.com/stock/ktta/news/expected-earnings-pasithea-therapeutics-corp--4503856933279955.html?utm_source=stocktwits

0 · Reply

daytradeforlife May. 11 at 4:34 PM

$KTTA averaged at .688 with 5000 shared and holding for the big one!

1 · Reply

johsmith May. 7 at 7:22 PM

$KTTA Started a position here at $0.81.

0 · Reply

focafoca99 May. 5 at 4:35 AM

$KTTA names a new chief medical officer and adds big option awards for executives and directors.

0 · Reply

Market Cap	14.74M
Revenue (ttm)	0.00
Net Income (ttm)	-20.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	149,552
Avg Vol	453,772
Day's Range	N/A - N/A
Shares Out	24.94M
Stochastic %K	32%
Beta	0.25
Analysts	Sell
Price Target	$3.00